17. Petrinec D, Holmes DR, Liao S, et al. Suppression of experimental aneurysmal degeneration with chemically modified tetracycline derivatives. Ann N Y Acad Sci. 1996; 800: 263–5.

18. Yu M, Chen C, Cao Y, et al. Inhibitory effects of doxycycline on the onset and progression of abdominal aortic aneurysm and its related mechanisms. Eur J Pharmacol. 2017 Sep 15; 811: 101-109;

19. Kurosawa K, Matsumura JS, Yamanouchi D. Current status of medical treatment for abdominal aortic aneurysm. Circulation journal: official journal of the Japanese Circulation Society. 2013; 77(12): 2860–2866.

20. Castro MM, Rizzi E, Prado CM, et al. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 2010 Apr; 29(3): 194-201.

21. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, et al. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg. 2009; 49(3): 741-9.

22. Lindeman JH, Abdul-Hussien H, van Bockel JH, et al. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 2009; 119(16): 2209-16.

23. Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth: a systematic review of the literature. Curr Vasc Pharmacol. 2011; 9: 471–8.

24. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011; 217: 57-63.

25. Meijer CA, Stijnen T, Wasser MN, et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med. 2013; 159: 815-23.

26. Baxter BT, Matsumura J, Curci J, et al. N-TA(3)CT Investigators. Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm. Contemp Clin Trials. 2016; 48: 91-8.

27. Ruddy JM, Jones JA, Ikonomidis JS. Pathophysiology of thoracic aortic aneurysm (TAA): is it not one uniform aorta? Role of embryologic origin. Prog Cardiovasc Dis. 2013 Jul-Aug; 56(1): 68-73. doi: 10.1016/j.pcad.2013.04.002. Epub 2013 May 15. Review.

28. Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007 May 15; 139(2): 292-307. Epub 2007 Feb 9. Review.

29. Chung AW, Au Yeung K, Sandor GG, et al. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res. 2007 Aug 31; 101(5): 512-22. Epub 2007 Jul 19

30. Chung AW, Yang HH, Radomski MW, et al. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008 Apr 25; 102(8): e73-85.

31. Mata KM, Prudente PS, Rocha FS, et al. Combining two potential causes of metalloproteinase secretion causes abdominal aortic aneurysms in rats: a new experimental model. Int J Exp Pathol. 2011; 92(1): 26-39.

32. Mata KM, Tefé-Silva C, Floriano EM, Fernandes CR, Rizzi E, Gerlach RF, Mazzuca MQ, Ramos SG. Interference of doxycycline pretreatment in a model of abdominal aortic aneurysms. Cardiovasc Pathol 2015; 24(2):110-20.

33. Mata KM, Fernandes CR, Tefé-Silva C, Floriano EM, Gerlach RF, Ramos SG. Response to the "letter regarding Interference of doxycycline pretreatment in a model of abdominal aortic aneurysms". Cardiovasc Pathol 2015;24(4):262-3.

34. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP- 1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998; 1;102(7):1413-20.

35. Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, Connolly ES. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 1997;41:642– 646.

36. Aoki T, Kataoka H, Moriwaki T, Nozaki K, Hashimoto N. Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms. Stroke 2007 Aug;38(8):2337-45).

37. Nishimura K, Ikebuchi M, Kanaoka Y, Ohgi S, Ueta E, Nanba E, Ito H. Relationships between Matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Int Angiol 2003;22:229 –238.

38. Higashikata T, Yamagishi M, Sasaki H, Minatoya K, Ogino H, Ishibashi-Ueda H, Hao H, Nagaya N, Tomoike H, Sakamoto A. Appli- cation of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. Atherosclerosis 2004;177:353–360.

39. Tsarouhas K, Soufla G, Apostolakis S, Zaravinos A, Panagiotou M, Khoury M, Hassoulas JA, Tsatsakis AM, Spandidos DA. Transcriptional regulation of TIMPs in ascending aorta aneurysms. Thromb Res. 2010;126(5):399-405.

40. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009536.Review.

41. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008 Apr 8;117(14):1883-9. Review.